Camille L. Bedrosian, MD
About Camille L. Bedrosian, MD
Camille L. Bedrosian, MD - Title
Camille L. Bedrosian, MD, currently holds the position of Chief Medical Officer. In her role, she oversees medical and clinical initiatives, ensuring the alignment of medical strategies with overall company objectives.
Camille L. Bedrosian, MD - HELIOS Study Involvement
Camille L. Bedrosian, MD, is actively involved in the HELIOS study, which focuses on evaluating AMX0035 for the treatment of Wolfram syndrome. Wolfram syndrome is a rare neurodegenerative disease. Her work in this study contributes to advancing understanding and potential treatment options for this complex condition.
Camille L. Bedrosian, MD - ORION Study Contributions
Dr. Bedrosian is playing a significant role in the ORION study, which aims to evaluate AMX0035 for the treatment of progressive supranuclear palsy. This study represents an important effort in investigating new therapeutic avenues for addressing this debilitating neurological disorder.
Camille L. Bedrosian, MD - Upcoming Clinical Trial for AMX0114 in ALS
Camille L. Bedrosian, MD, is planning to initiate a clinical trial to study AMX0114 for the treatment of ALS (Amyotrophic Lateral Sclerosis) in the second half of the year. She believes that AMX0114 holds strong potential not only for ALS but also for other diseases, highlighting her ongoing commitment to pushing the boundaries of medical research and treatment possibilities.